A phase II pilot study investigating the efficacy and activity of single agent GM-CSF (Leukine) maintenance approach in androgen-independent prostate cancer (AIPC) patients responding to Taxotere chemotherapy
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Sargramostim (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 19 Sep 2007 End date updated from NCT.
- 16 Oct 2006 New trial record.